Clinical trial
A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
NCT05029609 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
- Lead sponsor
- Tiziana Life Sciences LTD
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- October 31, 2021
- Completion date
- December 31, 2022
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis